Aquestive Therapeutics, Inc. AQST Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Indivior Pharmaceuticals, Inc.INDV

$32M-23.8%

ViatrisVTRS

$287.5M+7.9%

AMP

Amphastar PharmaceuticalsAMPH

$27.4M—

Avalo TherapeuticsAVTX

$242K-64.4%

BioCryst PharmaceuticalsBCRX

$12.52M+40.9%

PrecigenPGEN

$4.73M-12.7%

FAQ

What is Aquestive Therapeutics, Inc.'s operating lease liabilities (total)?

Aquestive Therapeutics, Inc. (AQST) reported operating lease liabilities (total) of $8.35M in Q2 2026.

How has Aquestive Therapeutics, Inc.'s operating lease liabilities (total) changed year-over-year?

Aquestive Therapeutics, Inc.'s operating lease liabilities (total) increased by 59.3% year-over-year, from $5.24M to $8.35M.

What is the long-term trend for Aquestive Therapeutics, Inc.'s operating lease liabilities (total)?

Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s operating lease liabilities (total) has grown at a 6.8% compound annual growth rate (CAGR), from $3.57M to $4.97M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.